Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions
Executive Summary
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
You may also be interested in...
Ovid Starts Neurology Spree With AstraZeneca Deal
The company is using proceeds from last year’s handover of its lead epilepsy program to Takeda to fuel a push in neurology development.
Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.
$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.